

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/39425</b> <b>(43) International Publication Date:</b> 11 September 1998 (11.09.98)
<b>(21) International Application Number:</b> PCT/US98/04155 <b>(22) International Filing Date:</b> 5 March 1998 (05.03.98) <b>(30) Priority Data:</b> 60/037,196 5 March 1997 (05.03.97) US <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> NEVILLE, David, M. [US/US]; 9624 Parkwood Drive, Bethesda, MD 20814 (US). <b>(74) Agents:</b> SPRATT, Gwendolyn, D. et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Atlanta, GA 30303 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). <b>Published</b> Without international search report and to be republished upon receipt of that report.

**(54) Title:** NOVEL VECTORS AND EXPRESSION METHODS FOR PRODUCING MUTANT PROTEINS



**(57) Abstract**

The present invention describes a new shuttle vector permitting the expression of engineered toxin mutants and toxin fusion proteins in *Corynebacterium*. In addition the invention provides a mutant *Pichia pastoris*, a method for producing this mutant and a method of expressing engineered toxin mutants and toxin fusion proteins in the mutant form of *Pichia pastoris*. The invention further provides a mutant Chinese hamster ovary (CHO) cell, a mutant insect cell, a method for producing these mutants and a method of expressing engineered toxin mutants and toxin fusion proteins in the mutant cells.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL VECTORS AND EXPRESSION METHODS  
FOR PRODUCING MUTANT PROTEINS

BACKGROUND OF THE INVENTION

5

Field of the Invention

The invention relates to novel expression systems and vectors for engineered immunotoxins. More specifically the invention relates to a shuttle vector for *E. coli* and  
10 *Corynebacteria*. The invention also relates to a method of expressing engineered toxin mutants and toxin fusion proteins in a mutant form of *Pichia pastoris*, a mutant form Chinese hamster ovary cells, and mutant insect cells and a methods for producing these mutants.

15

Background Art

U.S. Patent No. 5,167,956 describes *in vivo* T cell killing of 3 logs by immunotoxin anti-CD3-CRM9 or derivatives. This patent also describes the treatment of  
20 graft versus host disease, autoimmune disease and T cell leukemia.

A shuttle vector constructed for use in *Corynebacterium* and *E. coli* must contain a replication  
25 region (*oriR*) and a selectable marker that function in both host bacteria, or contain an *oriR* functional in *E. coli* and an chromosomal integrative mechanism functional in *Corynebacterium*. A naturally occurring plasmid, *pNG2*, isolated from an erythromycin-resistant *Corynebacterium*  
30 strain fulfills the former criteria (3). However this vector is large (14.4 kb), which reduces its

transformation frequency, which is additionally severely compromised by restriction incompatibilities between *Corynebacterium* and *E. coli* DNA (4). In addition multiple cloning sites are not present in pNG2 which are required  
5 to facilitate splicing inserts of toxin and fusion protein toxin genes into the vector.

Thus, the invention meets an important need for an *E. coli* and *Corynebacteria* shuttle vector with multiple  
10 cloning sites.

#### SUMMARY OF THE INVENTION

The present invention describes a new shuttle vector  
15 permitting the expression of engineered toxin mutants and toxin fusion proteins in *Corynebacterium*. In addition the invention provides a mutant *Pichia pastoris*, a method for producing this mutant and a method of expressing engineered toxin mutants and toxin fusion proteins in the  
20 mutant form of *Pichia pastoris*. The invention further provides a mutant Chinese hamster ovary (CHO) cell, a method for producing this mutant and a method of expressing engineered toxin mutants and toxin fusion proteins in the mutant CHO cells. These three systems  
25 have distinct advantages over *E. coli* expression systems because of their higher yields of secretion into the media compared to *E. coli* (1) thus eliminating the need for refolding procedures from insoluble aggregates (2). Refolding procedures employing denaturing agents although  
30 somewhat successful for single chain fusion proteins will not correctly refold divalent single chain fusion proteins

due to their greater complexity. Because divalent immunotoxins are necessary for successful *in vivo* clinical application, the present expression system for engineered immunotoxins is the key to producing a successful  
5 immunotoxin.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 depicts the method for producing an *E. coli*/*Corynebacterium* shuttle vector from the plasmid pNG2.  
10

Fig. 2 depicts the new *E. coli*/*Corynebacterium* shuttle vector, yCE96, containing nucleotides 1-3476 as shown in SEQ ID NO:1. Residues from positions 1 to 373  
15 and 2153 to 3476 are from the vector LITMUS 29 and contain the polycloning linker sites and the ampicillin resistance marker respectively. Residues from positions 374 to 2152 were the origin sequences from the plasmid pNG2.

20 Fig. 3a depicts a single chain divalent antibody-mutant-toxin fusion protein produced in *Corynebacterium*. The toxin is CRM9 and is preceded by the CRM9 promoter and signal sequence. VL and VH linked by a spacer described in U.S. Serial No. 08/739,703, herein  
25 incorporated by reference, are from UCHT1.  $\mu$ CH3 and  $\mu$ CH2 are from human IgM. The fusion protein forms the disulfide dimer from the cysteine between the CH2 and CH3 domains during or shortly after secretion. The gene for this fusion protein is constructed by PCR overlap  
30 extension to avoid cloning CRM9 until its toxicity is further reduced by a second genetic event, in this case an

additional carboxy terminal protein domain (NIH guidelines, see reference 20).

Fig. 3b shows a double mutant of DT containing the  
5 S525F mutation of CRM9 plus an additional replacement  
within the 514-525 exposed binding site loop to introduce  
a cysteine coupling site for example T521C can be produced  
in *Corynebacterium ulcerans* preceded by the CRM9 promoter  
and signal sequence. Residue numbering is based on the  
10 sequence provided by Shen et al. (17). The double mutant  
is made in *Corynebacterium ulcerans* by a recombination  
event between the plasmid producing CRM9-antibody fusion  
protein and PCR generated mutant DNA with a stop codon at  
526. This CRM9-C's can be used to form specific thioether  
15 mutant toxin divalent antibody constructs by adding excess  
bismaleimido-hexane to CRM9-C's and coupling to single  
chain divalent antibody containing a free cysteine at  
either the end of the  $\mu$ CH4 domain or the  $\mu$ CH3 domain.

## 20 DETAILED DESCRIPTION OF THE INVENTION

Provided is an *E. coli*/*Corynebacterium* shuttle vector  
comprising the origin of replication of shuttle vector  
pNG2, polycloning linker sites, and an antibiotic  
25 resistance marker with a size less than 4 kb. There are  
multiple possibilities for the polylinker cloning site and  
antibiotic resistance marker, which can be selected from  
those known or later developed. An example of the vector  
described above is yCE96. The sequence of yCE96 is given  
30 below.

The vector can further comprise an insert consisting of a protein-encoding nucleic acid. The encoded protein can contain a disulfide bond. For example, the protein-encoding nucleic acid can encode the binding site mutant DT toxin, CRM9. Alternatively, the protein-encoding nucleic acid can encode a CRM9 further comprising a second attenuating mutation. The second attenuating mutation can be the insertion of a COOH terminal protein domain. The second attenuating mutation can be a COOH terminal mutation that reduces binding activity, but not translocating activity. The second attenuating mutation can be selected from the group consisting of S508F, Y514A/C, K516A/C, V523A/C, N524A/C, K526A/C and F530A/C.

A protein encoding nucleic acid construct of the invention can include a mutation that introduces a cysteine residue into CRM9 or its derivatives. For example, the mutation can be selected from the group consisting of K530C, K516C, D519C and S535C.

A protein encoding nucleic acid construct of the invention can include a mutation that introduces residues or the replacement of residues in CRM9 or its derivatives, to attenuate the blocking effects of anti-diphtheria toxin antibodies. Examples of these mutations are described in the related applications.

A vector of the invention can further comprise the CRM9 iron-independent promoter, wherein the protein-encoding nucleic acid encodes a binding site mutant of diphtheria toxin, and the protein-encoding nucleic acid is

under the control of the CRM9 iron-independent promoter and is preceded by the CRM9 signal sequence.

A method of expressing a diphtheria toxin moiety or  
5 other protein is provided. The expression method  
comprises transfecting a *Corynebacterium ulcerans* or a  
*Corynebacterium diphtheriae* cell with a vector of the  
invention under conditions that permit expression of the  
protein-encoding nucleic acid. The conditions required  
10 for expression are the same as those previously used or  
described herein, including limited iron in the medium.

A method of making a vector of the invention is  
provided. For example the method comprises a) deleting  
15 COOH terminal base pairs of the attenuated CRM9 toxin-  
encoding nucleic acid using the restriction site Sph I at  
the toxin nucleotide position 1523 and a restriction site  
used to clone the COOH terminal part of the toxin into the  
polylinker cloning sites of yCE96, to produce a gapped,  
20 linear, plasmid deleted in the COOH terminal coding  
region; b) amplifying a product that corresponds to the  
COOH terminal region of CRM9 deleted in step a), with a  
PCR primer that includes the desired mutation and 30-40  
base pairs homologous to the down stream and upstream  
25 regions adjacent to the deletion; c) purifying the  
amplified product of step b) on an electrophoretic gel;  
and d) electroporating the product of step c) into a  
*Corynebacterium* along with the gapped plasmid of step a),  
under conditions which permit homologous recombination to  
30 occur intracellularly.



A method of mutating a protein-encoding nucleic acid in a vector of the invention is provided. The method can comprise a) deleting a region of the COOH terminus-encoding nucleotides of the protein-encoding nucleic acid  
5 using a unique restriction site and a restriction site used to clone the COOH terminal part of the toxin into the polylinker cloning sites of the shuttle vector, to produce a gapped, linear plasmid deleted in the COOH terminal coding region is produced; b) amplifying a product that  
10 corresponds to the COOH terminus-encoding region deleted in step a), using a PCR primer that includes the desired mutation and 30-40 base pairs homologous to the downstream and upstream regions adjacent to the deletion; c)  
15 purifying the amplified product of step b) on an electrophoretic gel; and d) electroporating the purified product of step c) into a *Corynebacterium* along with the gapped plasmid of step a), under conditions which permit homologous recombination to occur intracellularly.

20 The *Corynebacterium* used in the methods of making the present vectors or mutating proteins can be *Corynebacterium ulcerans*. Alternatively, the *Corynebacterium* can be a *Corynebacterium diphtheriae*, which has been mutated by chemical mutagenesis to exhibit  
25 less DNA restriction. Any number of mutations can accomplish this. The presence of the desired mutation is measured by a reduction in restriction in the organism. For example, this can be determined by measuring the efficiency of transformation, i.e., if number of  
30 transformants per  $\mu\text{g}$  of vector DNA increases over wild type or other mutants.

A mutant strain of *Pichia pastoris* is provided. The mutant strain comprises a mutation in at least one gene encoding elongation factor 2 (EF2). This the mutation comprises a Gly>Arg replacement at a position two residues  
5 to the carboxyl side of the modified histidine residue diphthamide. In this manner, the strain is made resistant to the toxic ADP-ribosylating activity of diphtheria and pseudomonas toxins.

10 A method of expressing a diphtheria toxin protein moiety or a pseudomonas exotoxin A toxin protein moiety is provided. Such a method of the invention comprises transfecting a mutated *Pichia* cell of the invention with a vector comprising a toxin protein-encoding nucleic acid  
15 under conditions that permit expression of the protein-encoding nucleic acid in the cell. The conditions are those used for *Pichia* cells and can be optimized for the particular system.

20 In an expression method using a mutant *Pichia* strain, the encoded protein is glycosylated in the cell to produce of immunotoxins that are resistant to the blocking effects of anti-diphtheria toxin antibodies on the T cell depleting function of CRM9-containing immunotoxins in  
25 human patients *in vivo*. There is a consensus sequence for glycosylation (NXS/T), which may be removed or inserted to control glycosylation which occurs in all eukaryotes, e.g., *Pichia*.

30 A method of expressing a diphtheria toxin or a pseudomonas exotoxin A toxin in Chinese hamster ovary

(CHO) cells, insect cells or other eukaryote cells is provided. The method can comprise first making a mutant strain of cells, comprising a mutation in at least one gene encoding elongation factor 2 (EF2), wherein the  
5 mutation comprises a Gly>Arg replacement at a position two residues to the carboxyl side of the modified histidine residue diphthamide, and the strain is resistant to the toxic ADP-ribosylating activity of diphtheria and pseudomonas toxins. This homologous recombination method  
10 can be used in any eukaryote, due to the high conservation of diphthamide in eukaryotes. Then the mutant cells are transfected with a vector of a type appropriate for the particular cell used, under conditions that permit expression of protein-encoding nucleic acid in the cells.  
15 The conditions can be those used for CHO cells and can be routinely optimized for the particular system and cells used.

As with the *Pichia*-expressed nucleic acids, the CHO  
20 method produces a glycosylated protein. This can produce immunotoxins that are resistant the blocking effects of anti-diphtheria toxin antibodies on the T cell depleting function of CRM9-containing immunotoxins in human patients *in vivo*.

25

30

## EXAMPLES

### Example 1

#### A *Corynebacterium*/Escherichia coli Shuttle Vector for Gene Expression

In brief, a new shuttle vector is constructed using the oriR of pNG2 and the antibiotic resistance marker and multiple cloning sites of the vector Litmus p29 (New  
10 England Bio Labs, Inc. Figure 1 depicts a method of making of a vector according to the invention. The new vector, yCE96, is only 3.4 kb in size and can transform both *E. coli* and *Corynebacterium ulcerans* and, thus, can be used to produce toxins and mutant toxins (5).

15

#### Cloning OriR from pNG2 plasmid:

pNG2 plasmid DNA was purified from *E. coli* JM109 strain. The 2.6 kb fragment containing oriR was released from pNG2 plasmid by restriction digestion with EcoRI and  
20 ClaI endonuclease. After separation and isolation, the 2.6 kb fragment was cloned into pBR322 vector (4361 bp) by the same two restriction sites EcoRI and ClaI, to form a construct of pBRNG with a size of 6.96 kb. This new vector is of limited use, because of its relatively large  
25 size and lack of multiple cloning sites.

#### Sub cloning pNG2 plasmid OriR to Generate a New Vector:

To generate a functional expression vector in  
*Corynebacterium* with a small size and a multiple cloning  
30 sites, the oriR DNA fragment, released from pBRNG constructs, is combined with a DNA fragment borrowed from

vector litmus p29. The DNA fragment containing the pNG2  
oriR was released from pBRNG vector by endonucleases EcoRI  
and SnaBI, and decreased in size from 2.6 kb to 1.77 kb by  
cleavage with these enzymes. It is noted that the  
5 sequence of the oriR is published, such that it could be  
constructed without the pNG2 plasmid. Its nt numbers are  
374-2152 in the sequence disclosed for yCE96. The DNA  
fragment borrowed from litmus 29 vector was released by  
restriction enzyme SnaBI and DraIII, and contains an  
10 ampicillin resistant gene and a multiple cloning sites.  
The two DNA pieces could not be ligated together, because  
the sticky end of the EcoRI site was not compatible with  
the sticky end of DraIII. To turn the sticky end into a  
blunted end, these DNA fragments were treated with T4  
15 polymerase in the presence of 0.1 mM dNTP.

After digestion with restriction enzymes SnaBI and  
DraIII, and treatment with T4 polymerase in the presence  
of 0.1 mM dNTP, the litmus 29 vector DNA was  
20 dephosphorylated with alkaline phosphatase to remove the  
5' phosphate group. The recombined vector was selected by  
transformation of the ligation mixture into Novablue *E.*  
*coli* cells. Five colonies were picked up. All of them  
contained a plasmid vector. The restriction digestion  
25 patterns of purified DNA from these five colonies  
demonstrated that four colonies contained the correct  
vector size of 3.4 kb.

The selection of endonuclease to release the oriR  
30 from pBRNG was based on the nucleotide sequence of plasmid  
pNG2 oriR identified by Messerotti et al.(6). The

replication region of pNG2 is 1854 bp, consists of a single oriR and one major open reading frame. When digested with SnaBI, 75 nucleotides were deleted from 5' end of the identified 1.85 kb oriR sequence. Therefore, the oriR cloned into the new vector, yCE96, was 75 nucleotides smaller than the previously identified 1.85 kb oriR sequence of plasmid pNG2, that is 1779 bp.

#### **Transformation of *Corynebacterium* and *E. coli* by yCE96**

*E. coli* cells were rendered competent by overnight growth followed by resuspension in LB medium containing 10% PEG 8000, 5% DMSO and 50 mM MgCl<sub>2</sub>, pH 6.5. The cells were heat shocked in the presence of 20 ng of vector DNA per 10<sup>6</sup> cells. *C. ulcerans* were converted to protoplasts as described (4) and transformed by electroporation of 40 µg of vector DNA (4).

Unless they have undergone transformation by yCE96, no colonies of *Corynebacterium ulcerans* or *E. coli* grow up under the selection pressure of the presence of carbenicillin. Many colonies are formed after transformation of *E. coli* cells and *C. ulcerans* with the yCE96 vector on the LB plate with 0.1 mg/ml of carbenicillin. The results demonstrate that yCE96 can stably transform *E. coli* and *C. ulcerans*; thus it is an effective shuttle vector between *E. coli* and *C. ulcerans*.

yCE96 is used to introduce foreign proteins into *C. ulcerans*, for example, diphtheria toxin mutants made by PCR site directed mutagenesis. To this end the CRM9 promoter carrying the iron-insensitive mutation (see U.S.

Serial No. 08/739,703, hereby incorporated by reference), as well as the toxin signal sequence have been cloned from CRM9 chromosomal DNA and precede mutant toxin constructs and mutant toxin single chain antibody fusion proteins.

5 Thus, high level synthesis of these engineered proteins, and their secretion into the medium, is expected. Insertion of tandem repeats of these protein-encoding constructs into yCE96 can also be made to achieve even higher production levels. Several constructs and their

10 uses are detailed in Fig. 3 and Fig. 3 legend.

### Example 2

#### Corynebacteriophage-based Vector

An alternate type of shuttle vector containing the

15 integrative mechanism of Corynebacteriophages can be constructed by cloning the corynephage attachment site (attP) and the integrase gene (int) sites from beta Corynebacteriophages into small *E. coli* vectors such as pUC19) not capable of replicating in Corynebacteriae.

20 Addition of another protein coding sequence such as modified CRM sequences (see below) will permit the integration of these sequences into tox-Corynebacteriae. These sequences can be further modified by excision followed by a gapped plasmid methodology described below

25 using a PCR product to achieve any desired mutation or combination of mutations. An advantage of the integrative vector is that it recombines at high efficiency.

### Example 3

#### Using Shuttle Vector yCE96 to Perform Site-Specific Mutagenesis On Diphtheria Toxin Binding Site Mutants in *Corynebacteria*

5

A binding site mutant of full length diphtheria toxin residues 1-535 (16) S525F (17) is further modified for chemical coupling by changing a residue in the binding domain (residues 379-535) to cysteine. Preferred residues  
10 are those with exposed solvent areas greater than 38%. These residues are K516, V518, D519, H520, T521, V523, K526, F530, E532, K534 and S535 (17). Of these, K516 and F530 are presently preferred, since they are likely to block any residual binding activity (17). However,  
15 maximal coupling of the new cysteine residue will be enhanced by the highest exposed solvent surface and proximity to a positively charged residue (which has the effect of lowering cysteine -SH pKa). These residues are at D519 and S535, so that these are also preferred from  
20 the above list of possibilities.

These mutations are accomplished by gapped plasmid PCR mutagenesis (18) using the newly designed *E. coli*/*C. ulcerans* shuttle vector yCE96 containing either the double  
25 mutant DT S508F S525F or a CRM9 COOH terminus fusion protein construct having reduced toxicity due to the COOH terminal added protein domain (19). Both of these constructs follow current NIH guidelines for cloning DT derivatives into *E. coli* (Federal Register, Notices,  
30 May 7, 1986), Appendix F-II-B, p. 16971) in that they contain two mutations which both individually diminish



toxicity and, therefore, greatly reduce the chance of introducing a wild type toxin into *E. coli* by a single base pair reversion. This mutation is made by deleting the COOH terminal 52 base pairs of the toxin construct using the restriction site Sph I at the toxin nucleotide position 1523 (16) and the restriction site used to clone the COOH terminal part of the toxin into the polylinker cloning sites of yCE96 (Xba or BamHI for example). Since Sph I, Xba, and BamHI only occur singly within vector yCE96 containing the inserted toxin construct, a gapped, linear plasmid, deleted in the COOH terminal coding region is the result. Using PCR the COOH terminal region of CRM9 is rebuilt introducing the desired mutation and including 30-40 base pairs homologous to the down stream and upstream regions adjacent to the gap. The amplified product is gel purified and electroporated into *C. ulcerans* along with the gapped plasmid (18).

Recombination at the homologous regions occurs intracellularly, accomplishing site specific mutagenesis of DT products within *Corynebacteriae* which are not specifically subject to NIH toxin cloning restrictions (20).

Using methods analogous to those described above, but with different restriction enzymes, mutagenesis can be performed anywhere within the toxin molecule. This would be highly useful for the construction of toxin B chain mutations having full translocating activity that are relatively free from the antitoxin blocking activity variably present in the sera of patient populations

resulting from prior immunizations with diphtheria toxoid. Because of the unique features of the present vector, a virtually unlimited number of mutated proteins can be expressed.

5

#### Example 4

##### Expression of mutant ADP-ribosylating toxins and toxin fusion proteins in an EF2 mutant of *Pichia pastoris*

10

The invention provides a system for expressing mutant ADP-ribosylating toxins and toxin fusion proteins in a *Pichia pastoris* mutant. The presently preferred mutant is one that has been rendered insensitive to these toxins by substituting arginine for glycine at a position two amino acids carboxyl to the modified histidine residue diphthamide (position 701 in the EF2 gene based on the numbering system in *S. cerevisiae*).

20

This mutation has been performed in *S. cerevisiae* and prevents toxin induced ADP-ribosylation rendering the toxin inactive (7). However, the literature has not described or proposed the use of this mutation to generate mutant cells for toxin production. To date, all DT based mutant toxins generated by site directed mutagenesis have been expressed in *E. coli*. To date, toxin mutants generated by the application of mutating reagents which are not site specific have only been produced in *C. diphtheriae* and *E. coli*.

30

Among the advantages of using this mutant *Pichia* are that for antibody toxin fusion proteins, which must have appropriate folding of critical antibody disulfide bonds, the endoplasmic reticulum compartment of the eukaryote yeast offers a similar oxidizing environment to natural eukaryote antibody producing cells such as hybridomas. *Pichia pastoris* has numerous advantages over *S. cerevisiae* (8), including the observation that, for therapeutic proteins, the glycosylation pattern of *Pichia* is much more similar to that of humans compared to *S. cerevisiae*.

The *Pichia* mutant can be constructed by direct transformation of yeast spheroplasts with a mutating oligonucleotide complimentary to the sense strand of *S. cerevisiae* EF2 in the region of the desired mutation but not at the desired mutation (9). Since homology in this area is very high across phyla (10), this sequence will very likely undergo homologous recombination in *P. pastoris*. One example of such a mutating oligonucleotide has the following sequence:

5-GTT ACT TTA CAT GCC GAT GCT ATC CAC AGA AGA GGT GGT CAA  
ATC ATC CCA-3 (SEQ ID NO:2)

The arginine substitution has been underlined. This nucleic acid can be modified, for example, by shortening on both ends, but this may result in reduced recombination frequency.

The transformation is done in the presence of 10  $\mu$ M wild type diphtheria toxin or a binding site mutant DT

toxin, such as CRM9, as a selecting agent (11). Several repeat rounds of selection can be utilized. The final selection is performed by transforming *Pichia* with a toxin-containing construct, which will inhibit growth in  
5 any cells which lack toxin-resistance mutation in EF2.

The invention also provides a *Pichia* EF2 toxin-resistant clone, which is free of toxin-encoding constructs, to be used for to express alternative  
10 constructs. This cell can be generated by popping out the construct via homologous recombination (12).

Many *Pichia pastoris* strains and *E. coli/Pichia* shuttle vectors are available (Invitrogen Corporation),  
15 and can be used in an expression system as described above. This technology will be useful for diphtheria toxin and pseudomonas exotoxin A constructs and fusion immunotoxins based on these toxins. The same mutant toxins and toxin-antibody fusion proteins produced in  
20 *Corynebacterium* shown in Fig 2 can also be produced in *P. pastoris*. The genetic constructs differ in that in *P. pastoris* the promotor is AOXI and the secretion or signal sequence is either PHO1 or @-factor. In addition certain codons unique to *Corynebacterium* may require changing in  
25 *P. pastoris*, as will some codons specifying potential glycosylation sites which would be active in *Pichia* but inactive in *Corynebacterium*. Alternatively, the introduction of glycosylation sites within the CRM9 gene could be used as a method to block antibodies directed at  
30 the toxin in patients with high antitoxin titers secondary to recent immunization with diphtheria toxoid.

**Example 5****Expression of mutant ADP-ribosylating toxins and toxin fusion proteins in an EF2 mutant of CHO cells.**

5 CHO cells have certain advantages for the production of fusion proteins used as therapeutic reagents: a) Hamster cells are relatively free from retrovirus contamination, b) Protein glycosylation patterns are relatively similar to that seen in humans, and c) CHO  
10 cells generally, respond well to gene amplification systems that increase the yield of proteins introduced through DNA transfection. Although it has been reported that mammalian cells can secrete an ETA based fusion protein without succumbing to ETA induced cytotoxicity via  
15 ADP-ribosylation (13), this situation is likely due to the resistance of ETA to proteolytic processing at pH >6.0, a feature not shared by DT. Therefore the production of DT based fusion immunotoxins must utilize a line of CHO cells that has been rendered DT insensitive by mutating EF2 by  
20 substituting arginine for glycine at a position two amino acids carboxyl to the modified histidine residue diphthamide (position 717 in the EF2 gene based on the numbering system in CHO cell EF2). Two such cell lines have been reported. RE1.22c (14) and KEE1 (15) were  
25 isolated by double rounds of chemical mutagenesis and selection with DT or ETA. These mutants were used to determine the physiologic role of diphthamide, the modified histidine residue whose formation is blocked by this mutation. No mention is made in the art of using these  
30 cells to make toxins or immunotoxins. The same procedure can be applied to other eukaryote cell lines expressing

toxin sensitivity, such as insect cell lines. These lines have the advantage of secreting large amounts of foreign proteins introduced through baculovirus (21).

5           Throughout this application various publications are referenced by numbers within parentheses. Full citations for these publications are as follows. The disclosures of these publications in their entireties are hereby  
10 to more fully describe the state of the art to which this invention pertains.

#### REFERENCES

1. Greenfield, L., *Targeted Diagnosis and Therapy*, Chapter 16, p. 307; 1992.
2. vanderSpek, J. C., Mindell, J. A., et al. *J. Biol. Chem.* 268:12077-82, 1993.
3. Serwold-Davis, T. M., Groman, N. B., et al. *FEMS Microbiology Letters.* 66:119-124, 1990.
4. Serwold-David, T. M., Groman, N. B., et al. *Proc. Natl. Acad. Sci.* 84:4964-4968, 1987.
5. Groman, N., Schiller, J., et al. *Infection and Immunity* 45:511-517, 1984.
6. Messerotti, L. J., Radford, A. J. et al. *Gene* 96:147-8, 1990.

7. Kimata, Y., Harashima, S., et al. *Biochemical and Biophysical Research Communications* 191:1145-1151, 1993.
8. Buckholz, R. G., and Gleeson, M. A. G. *Bio/Technology*. 9:1067, 1991.
9. Moerschell, R. P., Das, G., et al. *Methods in Enzymology*. 194:362, 1991.
10. Perenetesis, J. P., Phan, L. D., et al. *J. Biol. Chem.* 267:1190-1197, 1992.
11. Murakami, S., Bodley, J. W., et al. *Molecular and Cellular Biology* 2:588-592, 1982.
12. Rothstein, R. *Methods in Enzymology* 194:281, 1991.
13. Chen, S. Y. et al. *Nature* 385(2):78, January 2, 1997.
14. Foley, B.T. et al. *J. Biolog. Chem.* 370(39):23218-23225, September 29, 1995.
15. Kohno, K. and Uchida, T. *J. Biolog. Chem.* 262(25):12298-12305, 1987.
16. Kaczorek M, Delpeyroux F, Chenciner N, Streeck R (1983) *Science*; 221:855.
17. Shen WH, Choe S, Eisenberg D, Collier RJ (1994) . *Biol. Chem.*; 469(46):29077-29084.

18. Muhlrad D, Hunter R, Parker R (1992) Yeast; 8:79-82.
19. Madshus IH, Stenmark H, Snadvig K, Olsnes S (1991) J. Biol. Chem.; 266(26):17446-53.
20. Federal Register, Notices, May 7, 1986), Appendix F-II-B, p. 16971.
21. Bei, R, Schlom, J and Kashmiri, SVS (1995) J. Immunol. Meth.; 186:245-255.



## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
- (ii) TITLE OF THE INVENTION: NOVEL VECTORS AND EXPRESSION METHODS FOR PRODUCING MUTANT PROTEINS
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: NEEDLE & ROSENBERG, P.C.
  - (B) STREET: 127 Peachtree Street, N.E., Suite 1200
  - (C) CITY: Atlanta
  - (D) STATE: GA
  - (E) COUNTRY: USA
  - (F) ZIP: 30303-1811
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 05-MAR-1998
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 60/037,196
  - (B) FILING DATE: 05-MAR-1997
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Spratt, Gwendolyn D.
  - (B) REGISTRATION NUMBER: 36,016
  - (C) REFERENCE/DOCKET NUMBER: 14014.0286/P
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 404 688 0770
  - (B) TELEFAX: 404 688 9880
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3476 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAAAAAAAGC	CCGCCGAAGC	GGGCTTTATT	ACCAAGCGAA	GCGCCATTCTG	CCATTTCAGGC	60
TGCGCAACTG	TTGGGAAGGG	CGATCGGTGC	GGGCCTCTTC	GCTATTACGC	CAGCTGGCGA	120
AAGGGGGATG	TGCTGCAAGG	CGATTAAGTT	GGGTAAACGCC	AGGGTTTTCC	CAGTCACGAC	180
GTTGTAAAC	GACGGCCAGT	CCGTAATACG	ACTCACTTAA	GGCCTTGACT	AGAGGGAAGA	240
TCTGGATGCA	TTCGCGCGCA	CGTACGGTCT	CGAGGAATTC	CTGCAGGATA	TCGTGGATCC	300
AAGCTTCACC	ATGGGAGACG	TCACCGGTTC	TAGAACCCTAG	GGAGCTCTGG	TACCCACTAG	360
TGAGTCGTAT	TACGTAACCG	CAGGTAAAAG	GCATATTTTT	CGCGTGTCTAT	GGCTAGTAAA	420
TAACACCGGT	GTCATTTAGA	GTCAGGGAAA	GACAATGAAA	AACGAAGAAA	GCCACCGGGC	480
GGCAACCCGA	TGACTTTCGC	TTATCACCCA	GCACACACCT	GGGAGAAATC	ACGGTCATGA	540
GTTTACAGAC	TCATGCGCAG	AATGCGCACA	CTAAAACACC	TACCCGCGTC	GAGCGCGACC	600
GTGGTGGACT	GGACAACACC	CCAGCATCTG	CCAGTGACCG	CGACCTTTTA	CGCGATCATC	660
TAGGCCGCGA	TGTACTCCAC	GGTTCAGTCA	CACGAGACTT	TAAAAAGGCC	TATCGACGCA	720
ACGCTGACGG	CACGAACTCG	CCGCGTATGT	ATCGCTTCGA	GACTGATGCT	TTAGGACGGT	780
GCGAGTACGC	CATGCTCACC	ACCAAGCAGT	ACGCCGCCGT	CCTGGTCGTA	GACGTTGACC	840
AAGTAGGTAC	CGCAGGCGGT	GACCCCGCAG	ACTTAAACCC	GTACGTCCGC	GACGTGGTGC	900
GCTCACTGAT	TACTCATAGC	GTCGGGCCAG	CCTGGGTGGG	TATTAACCCA	ACTAACGGCA	960
AAGCCAGTGT	CATATGGCTT	ATTGACCCTG	TCTACGCTGA	CCGTAACGGT	AAATCTGCGC	1020
AGATGAAGCT	TCTTGACAGCA	ACCACGCGTG	TGCTGGGTGA	GCTTTTAGAC	CATGACCCGC	1080
ACTTTTCCCA	CCGCTTTAGC	CGCAACCCGT	TCTACACAGG	CAAAGCCCCT	ACCGCTTATC	1140
GTTGGTATAG	CGAGCACAAC	CGGGTGATGC	GCCTTGGAGA	CTTGATAAAG	CAGGTAAGGG	1200
ATATGGCAGG	ACACGACCAG	TTCAACCCCA	CCCCACGCCA	GCAATTCAGC	TCTGGCCGCG	1260
AACTTATCAA	CGCGGTCAAG	ACCCGCCGTG	AAGAAGCCCA	AGCATTCAAA	GCACTCGCCC	1320
AGGACGTAGA	CGCGGAAATC	GCCGGTGGTC	TCGACCAGTA	TGACCCGGAA	CTTATCGACG	1380
GTGTGCGTGT	GCTCTGGATT	GTCCAAGGAA	CCGCAGCAGC	CGACGAAACA	GCCTTTAGAC	1440
ATGCGCTTAA	GACTGGCCAC	CGCTTGCGCC	AGCAAGGCCA	ACGCCTGACA	GACGCAGCAA	1500
TCATCGACGC	CTATGAGCAC	GCCTACAACG	TCGCACACAC	CCACGGCGGT	GCAGGCCGCG	1560
ACAACGAGAT	GCCACCCATG	CGCGACCGCC	AAACCATGGC	AAGGCGCGTG	CGCGGGTATG	1620
TCGCCCAATC	CAAGAGCGAG	ACCTACAGCG	GCTCTAACGC	ACCAGGTAA	GCCACCAGCA	1680
GCGAGCGGAA	AGCCTTGGCC	ACGATGGGAC	CGAGAGGCGG	ACAAAAAGCC	GCACAACGCT	1740
GGAAAAACAGA	CCCCGAGGCG	AAATATGCGC	AAGACCAAAG	GTCGAAGCTT	GAAAAGACGC	1800
ACCGTAAGAA	AAAGGCTCAA	GGACGATCTA	CGAAGTCCCG	TATTAGCCAA	ATGGTGAACG	1860
ATCAGTATTT	CCAGACAGGG	ACAGTTCCCA	CGTGGGCTGA	AATAGGGGCA	GAGGTAGGAG	1920
TCTCTCGCGC	CACGGTTGCT	AGGCATGTCG	CGGAGCTAAA	GAAGAGCGGT	GACTATCCGG	1980
ACGTTTAAGG	GGTCTCATAC	CGTAAGCAAT	ATACGGTTCC	CCTGCCGTTA	GGCAGTTAGA	2040
TAAAACCTCA	CTTGAAGAAA	ACCTTGAGGG	GCAGGGCAGC	TTATATGCTT	CAAAGCATGA	2100
CTTCCTCTGT	TCTCCTAGAC	CTCGCAACCC	TCCGCCATAA	CCTCACCGAA	TTGTGGGCCA	2160
TCGCCCTGAT	AGACGGTFTT	TCGCCCTTTG	ACGTTGGAGT	CCACGTTCTT	TAATAGTGGA	2220
CTCTTGTTCC	AAACTGGAAC	AACACTCAAC	CCTATCTCGG	GCTATTCTTT	TGATTTATAA	2280
GGGATTTTGC	CGATTTGCGC	CTATTGGTTA	AAAAATGAGC	TGATTTAACA	AAAATTTAAC	2340
GCGAATTTTA	ACAAAATATT	ACAGTTTACA	ATTTAAATAT	TTGCTTATAC	AATCTTCCTG	2400
TTTTTGGGGC	TTTTCTGATT	ATCAACCGGG	GTAAATCAAT	CTAAAGTATA	TATGAGTAAA	2460
CTTGGTCTGA	CAGTTACCAA	TGCTTAATCA	GTGAGGCACC	TATCTCAGCG	ATCTGTCTAT	2520
TTCGTTTCATC	CATAGTTGCC	TGACTCCCCG	TCGTGTAGAT	AACTACGATA	CGGGAGGGCT	2580
TACCATCTGG	CCCCAGTGCT	GCAATGATAC	CGCGAGACCC	ACGCTCACCG	GCTCCAGATT	2640
TATCAGCAAT	AAACCAGCCA	GCCGGAAGGG	CCGAGCGCAG	AAGTGGTCCT	GCAACTTTAT	2700
CCGCCCTCCAT	CCAGTCTATT	AATTGTTGCC	GGGAAGCTAG	AGTAAGTAGT	TCGCCAGTTA	2760
ATAGTTTGCG	CAACGTTGTT	GCCATTGCTA	CAGGCATCGT	GGTGTCACGC	TCGTGCTTGT	2820
GTATGGCTTC	ATTAGCTCC	GTTTCCCAAC	GATCAAGGCG	AGTTACATGA	TCCCCCATGT	2880
TGTGCAAAAA	AGCGGTTAGC	TCCTTCGGTC	CTCCGATCGT	TGTCAGAAGT	AAGTTGGCCG	2940
CAGTGTTATC	ACTCATGGTT	ATGGCAGCAC	TGCATAATTC	TCTTACTGTC	ATGCCATCCG	3000

TAAGATGCTT	TTCTGTGACT	GGTGAGTACT	CAACCAAGTC	ATTCTGAGAA	TAGTGTATGC	3060
GGCGACCGAG	TTGCTCTTGC	CCGGCGTCAA	CACGGGATAA	TACCGCGCCA	CATAGCAGAA	3120
CTTTAAAAGT	GCTCATCATT	GGAGAACGTT	CTTCGGGGCG	AAACTCTCA	AGGATCTTAC	3180
CGCTGTTGAG	ATCCAGTTTG	ATGTAACCCA	CTCGTGCACC	CAACTGATCT	TCAGCATCTT	3240
TTACTTTCAC	CAGCGTTTCT	GGGTGAGCAA	AAACAGGAAG	GCAAAATGCC	GCAAAAAGG	3300
GAATAAGGCG	GACACGGAAA	TGTTGAATAC	TCATACTCTT	CCTTTTCAA	TATTATTGAA	3360
GCATTTATCA	GGGTTATTGT	CTCATGAGCG	GATACATATT	TGAATGTATT	TAGAAAAATA	3420
AACAAATAGG	GGTTCCGCGC	ACATTTCCCC	GAAAAGTGCC	ACCTGACGTA	GTTAAC	3476

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTTACTTTAC ATGCCGATGC TATCCACAGA AGAGGTGGTC AAATCATCCC A

51

What is claimed is:

1. An *E. coli*/*Corynebacterium* shuttle vector comprising the origin of replication of shuttle vector pNG2, polycloning linker sites, and an antibiotic resistance marker with a size less than 4 kb.
2. The vector of claim 1, wherein the vector is yCE96.
3. The vector of claim 1, wherein the vector further comprises an insert consisting of a protein-encoding nucleic acid.
4. The vector of claim 3, wherein the encoded protein contains disulfide bonds.
5. The vector of claim 4, wherein the protein-encoding nucleic acid encodes a binding site mutant of diphtheria toxin,  
further comprising the CRM9 iron-independent promoter and the CRM9 signal sequence,  
wherein the protein-encoding nucleic acid is under the control of the CRM9 iron-independent promoter and is preceded by the CRM9 signal sequence.
6. The vector of claim 5, wherein the protein-encoding nucleic acid encodes CRM9.
7. The vector of claim 6, wherein the CRM9 further comprises a second attenuating mutation.

8. The vector of claim 7, wherein the second attenuating mutation is the insertion of a COOH terminal protein domain.

9. The vector of claim 7, wherein the second attenuating mutation is a COOH terminal mutation that reduces binding activity, but not translocating activity.

10. The vector of claim 7, wherein the second attenuating mutation is selected from the group consisting of S508F, Y514A/C, K516A/C, V523A/C, N524A/C, K526A/C and F530A/C.

11. A method of expressing a diphtheria toxin moiety, comprising transfecting a *Corynebacterium ulcerans* or a *Corynebacterium diphtheriae* cell with the vector of claim 1 under conditions that permit expression of the protein-encoding nucleic acid.

12. A method of making the vector of claim 7, comprising:

a) deleting COOH terminal base pairs of the attenuated CRM9 toxin-encoding nucleic acid using the restriction site Sph I at the toxin nucleotide position 1523 and a restriction site used to clone the COOH terminal part of the toxin into the polylinker cloning sites of yCE96, to produce a gapped, linear, plasmid deleted in the COOH terminal coding region;

b) amplifying a product that corresponds to the COOH terminal region of CRM9 deleted in step a), with a PCR primer that includes the desired mutation and 30-40

base pairs homologous to the down stream and upstream regions adjacent to the deletion;

c) purifying the amplified product of step b) on an electrophoretic gel; and

d) electroporating the product of step c) into a *Corynebacterium* along with the gapped plasmid of step a), under conditions which permit homologous recombination to occur intracellularly.

13. The method of claim 12, wherein the *Corynebacterium* is *Corynebacterium ulcerans*.

14. The method of claim 12, wherein the *Corynebacterium* is *Corynebacterium diphtheriae* mutated by chemical mutagenesis to exhibit less DNA restriction.

15. A method of making the vector of claim 5 comprising:

a) deleting a region of the COOH terminus-encoding nucleotides of the protein-encoding nucleic acid using a unique restriction site and a restriction site used to clone the COOH terminal part of the toxin into the polylinker cloning sites of the shuttle vector, to produce a gapped, linear plasmid deleted in the COOH terminal coding region;

b) amplifying a product that corresponds to the COOH terminus-encoding region deleted in step a), using a PCR primer that includes the desired mutation and 30-40 base pairs homologous to the downstream and upstream regions adjacent to the deletion;

c) purifying the amplified product of step b) on an

electrophoretic gel; and

d) electroporating the purified product of step c) into a *Corynebacterium* along with the gapped plasmid of step a), under conditions which permit homologous recombination to occur intracellularly.

16. The method of claim 15, wherein the *Corynebacterium* is *Corynebacterium ulcerans*.

17. The method of claim 15, wherein the *Corynebacterium* is *Corynebacterium diphtheriae* mutated to exhibit less DNA restriction.

18. The method of claim 15, wherein the protein-encoding nucleic acid encodes a protein containing a disulfide bond.

19. The method of claim 15, wherein the encoded protein is a binding site mutant of diphtheria toxin, further comprising the CRM9 iron-independent promoter,

wherein the protein-encoding nucleic acid is under the control of the CRM9 iron-independent promoter.

20. The method of claim 19, wherein the mutation is the introduction of a cysteine residue into CRM9 or its derivatives.

21. The method of claim 19, wherein the mutation is selected from the group consisting of K530C, K516C, D519C and S535C.

22. The method of claim 19, further comprising a second attenuating mutation, which is the insertion of a COOH terminal protein domain.

23. The method of claim 19, further comprising a second attenuating mutation, which is a COOH terminal mutation that reduces binding activity, but not translocating activity.

24. The method of claims 19, further comprising a second attenuating mutation selected from the group consisting of S508E, Y514A/C, K516A/C, V523A/C, N524A/C, K526A/C and F530A/C.

25. The method of claim 19, wherein the mutation is the introduction of residues or the replacement of residues in CRM9 or its derivatives, to attenuate the blocking effects of anti-diphtheria toxin antibodies.

26. A mutant strain of *Pichia pastoris*, comprising a mutation in at least one gene encoding elongation factor 2 (EF2),

wherein the mutation comprises a Gly>Arg replacement at a position two residues to the carboxyl side of the modified histidine residue diphthamide, whereby the strain is resistant to the toxic ADP-ribosylating activity of diphtheria and pseudomonas toxins.

27. A method of expressing a diphtheria toxin moiety or a pseudomonas exotoxin A toxin moiety, comprising transfecting the cell of claim 26 with a vector comprising



a toxin protein-encoding nucleic acid under conditions that permit expression of the protein-encoding nucleic acid in the cell.

28. The method of claim 27, wherein the encoded protein is glycosylated in the cell.

29. A method of expressing a diphtheria toxin or a pseudomonas exotoxin A toxin, comprising:

transfecting, with a vector of claim 3, under conditions that permit expression of protein-encoding nucleic acid, a mutant strain of Chinese hamster ovary cells, comprising a mutation in at least one gene encoding elongation factor 2 (EF2),

wherein the mutation comprises a Gly>Arg replacement at a position two residues to the carboxyl side of the modified histidine residue diphthamide,

whereby the strain is resistant to the toxic ADP-ribosylating activity of diphtheria and pseudomonas toxins.

30. The method of claim 29, wherein the encoded protein is glycosylated in the cell.

31. A method of expressing a diphtheria toxin or a pseudomonas exotoxin A toxin, comprising:

transfecting, with a vector of claim 3, under conditions that permit expression of protein-encoding nucleic acid, a mutant strain of insect cells, comprising a mutation in at least one gene encoding elongation factor 2 (EF2),

wherein the mutation comprises a Gly>Arg replacement at a position two residues to the carboxyl side of the modified histidine residue diphthamide,

whereby the strain is resistant to the toxic ADP-ribosylating activity of diphtheria and pseudomonas toxins.

32. The method of claim 31, wherein the encoded protein is glycosylated in the cell.

1/4



CLONING *oriR* FROM pNG2 PLASMIDSUBCLONING THE *oriR* TO GENERATE A NEW VECTOR

FIG. 1

2/4




FIG.2

3/4





FIG. 3a

4/4



**FIG. 3b**